Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,144,696
  • Shares Outstanding, K 965,433
  • Annual Sales, $ 24,556 M
  • Annual Income, $ 3,232 M
  • 60-Month Beta 0.16
  • Price/Sales 4.50
  • Price/Cash Flow 16.47
  • Price/Book 38.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 1.43
  • Number of Estimates 4
  • High Estimate 1.49
  • Low Estimate 1.33
  • Prior Year 1.39
  • Growth Rate Est. (year over year) +2.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.40 +8.13%
on 09/10/19
117.23 -1.86%
on 09/20/19
+5.54 (+5.06%)
since 08/23/19
3-Month
105.15 +9.42%
on 07/12/19
117.23 -1.86%
on 09/20/19
-0.44 (-0.38%)
since 06/21/19
52-Week
104.17 +10.44%
on 10/25/18
132.13 -12.93%
on 03/26/19
+8.72 (+8.20%)
since 09/21/18

Most Recent Stories

More News
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019

Eli Lilly and Company (NYSE: LLY) today announced data from a number of studies across the company's oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019...

LLY : 114.59 (-1.35%)
Psoriasis Drug Market: Industry Trends and Analysis - Growth Revenue And Cost Analysis With Key Company's Profiles, Forecast To 2025

unveils a succinct analysis of the market size, regional spectrum and revenue forecast about the Psoriasis Drug market. Furthermore, the report points out major challenges and latest growth plans embraced...

VRX.TO : 30.80 (-3.33%)
MRK : 84.55 (-0.72%)
NVS : 86.37 (-0.80%)
AMGN : 198.03 (+0.55%)
CELGZ : 0.57 (unch)
PFE : 36.42 (-0.74%)
LLY : 114.59 (-1.35%)
TKPYY : 16.5900 (-0.90%)
GSK : 41.92 (+0.70%)
BIIB : 240.81 (+0.85%)
CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an update to the Trulicity®...

LLY : 114.59 (-1.35%)
Relatively Good Performance Detected in Shares of Aerie Pharmaceut in the Pharmaceuticals Industry (AERI , MDCO , LLY , MRK , ZTS )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

AERI : 24.00 (+2.87%)
MDCO : 48.85 (-0.53%)
LLY : 114.59 (-1.35%)
Lilly Announces Webcast to Discuss ESMO 2019 Presentations

Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona,...

LLY : 114.59 (-1.35%)
Eli Lilly & Co Rises 1.47% on Heavy Volume: Watch For Potential Pullback

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $112.85 to a high of $114.43. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of...

LLY : 114.59 (-1.35%)
CANbridge Pharmaceuticals Fills Two Key Operational Positions, Vice President, Rare Disease and Head of Market Access

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, continues to deepen its operations...

LLY : 114.59 (-1.35%)
Shares of Lannett Co Inc Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (LCI , LLY , MRK , BMY , JNJ )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

LCI : 13.63 (-1.23%)
MRK : 84.55 (-0.72%)
LLY : 114.59 (-1.35%)
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

ALDR : 18.64 (unch)
LLY : 114.59 (-1.35%)
NVS : 86.37 (-0.80%)
AMGN : 198.03 (+0.55%)
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure

The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.

AZN : 44.82 (-0.80%)
JNJ : 130.58 (-0.81%)
LLY : 114.59 (-1.35%)
BMY : 50.83 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 118.71
1st Resistance Point 117.44
Last Price 114.59
1st Support Level 114.68
2nd Support Level 113.19

See More

52-Week High 132.13
Fibonacci 61.8% 121.45
Fibonacci 50% 118.15
Fibonacci 38.2% 114.85
Last Price 114.59
52-Week Low 104.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar